We are pleased to announce that funding has been awarded through the third competition of the Virtual Research Institute (WIB – Wirtualny Instytut Badawczy) for the project “ Targeted single-cell technology for cancer diagnostics – towards cell-oriented interceptive medicine” (acronym: INTERCEPT), led by Prof. Marek Figlerowicz.

The Virtual Research Institute is an innovative research funding program targeting studies with high commercialization potential in key areas for society, particularly medical biotechnology. The main goal of the INTERCEPT project is to revolutionize cancer diagnostics by developing independent microfluidic systems and nucleic acid-based technology enabling the analysis of single cells, which will subsequently be used to create targeted diagnostic tests. These envisioned tests will be applied in diagnosing acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). The project’s core idea is to introduce highly advanced single-cell analysis technologies into clinical practice by reducing technical complexity and costs and improving overall clinical utility.

The funding amount for the project is 40.2 million PLN (direct costs: 34,984,750 PLN, indirect costs: 5,232,712 PLN). The project is planned for 5 years, from July 1, 2024, to June 30, 2029.

More information on the competition results:
https://wib.port.org.pl/informacja-prasowa-trzeci-konkurs-rozstrzygniety/
https://wib.port.org.pl/wyniki-konkursu-3-2023/

Congratulations and best wishes for success in conducting the research!